Cortexyme (NASDAQ:CRTX) Stock Price Passes Above 200-Day Moving Average of $0.00

Cortexyme, Inc. (NASDAQ:CRTX) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $36.50. Cortexyme shares last traded at $35.20, with a volume of 957 shares traded.

CRTX has been the subject of several recent analyst reports. Bank of America initiated coverage on Cortexyme in a research report on Monday, June 3rd. They issued a “neutral” rating and a $28.00 price target for the company. Canaccord Genuity began coverage on Cortexyme in a research report on Monday, June 3rd. They issued a “buy” rating and a $42.00 price target for the company. Credit Suisse Group began coverage on Cortexyme in a report on Monday, June 3rd. They issued an “underperform” rating and a $14.00 price objective for the company. Finally, JMP Securities began coverage on Cortexyme in a report on Monday, June 3rd. They issued a “mkt outperform” rating and a $53.00 price objective for the company.

The stock has a fifty day moving average price of $38.61.

In other Cortexyme news, major shareholder Pfizer Inc acquired 50,000 shares of Cortexyme stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $850,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 12.40% of the stock is currently owned by company insiders.

Cortexyme Company Profile (NASDAQ:CRTX)

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.

See Also: What is the NASDAQ?

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.